Cargando…

The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up

Background: The wearable cardioverter-defibrillator (WCD) is available for patients at high risk for sudden cardiac death (SCD) when immediate implantable cardioverter-defibrillator (ICD) implantation is not possible or indicated. Patient selection remains challenging especially in primary preventio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenkaimer, Stephanie L., El-Battrawy, Ibrahim, Dreher, Tobias C., Gerhards, Stefan, Röger, Susanne, Kuschyk, Jürgen, Borggrefe, Martin, Akin, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141506/
https://www.ncbi.nlm.nih.gov/pubmed/32214048
http://dx.doi.org/10.3390/jcm9030893
_version_ 1783519207684571136
author Rosenkaimer, Stephanie L.
El-Battrawy, Ibrahim
Dreher, Tobias C.
Gerhards, Stefan
Röger, Susanne
Kuschyk, Jürgen
Borggrefe, Martin
Akin, Ibrahim
author_facet Rosenkaimer, Stephanie L.
El-Battrawy, Ibrahim
Dreher, Tobias C.
Gerhards, Stefan
Röger, Susanne
Kuschyk, Jürgen
Borggrefe, Martin
Akin, Ibrahim
author_sort Rosenkaimer, Stephanie L.
collection PubMed
description Background: The wearable cardioverter-defibrillator (WCD) is available for patients at high risk for sudden cardiac death (SCD) when immediate implantable cardioverter-defibrillator (ICD) implantation is not possible or indicated. Patient selection remains challenging especially in primary prevention. Long-term data on these patients is still lacking. Methods: 153 patients were included in this study. They were prescribed the WCD between April 2012 and March 2019 at the University Medical Center, Mannheim, Germany. The mean follow-up period was 36.2 ± 15.6 months. Outcome data, including all-cause mortality, were analyzed by disease etiology and ICD implantation following WCD use. Results: We analyzed 56 patients with ischemic cardiomyopathy, 70 patients with non-ischemic cardiomyopathy, 16 patients with prior need for ICD/CRT-D (device for cardiac resynchronization therapy with defibrillator) explanation, 8 patients with acute myocarditis and 3 patients with congenital diseases. 58% of the patients did not need ICD/CRT-D implantation after WCD use. 4% of all patients suffered from appropriate WCD shocks. 2 of these patients (33%) experienced appropriate ICD shocks after implantation due to ventricular tachyarrhythmias. Long-term follow-up shows a good overall survival. All-cause mortality was 10%. There was no significant difference between patients with or without subsequent ICD implantation (p = 0.48). Patients with ischemic cardiomyopathy numerically showed a higher long-term mortality than patients with non-ischemic cardiomyopathy (14% vs. 6%, p = 0.13) and received significantly more ICD shocks after implantation (10% of ischemic cardiomyopathy (ICM) patients versus 3% of non-ischemic cardiomyopathy (NICM) patients, p = 0.04). All patients with ventricular tachyarrhythmias during WCD use or after ICD implantation survived the follow-up period. Conclusion: Following WCD use, ICD implantation could be avoided in 58% of patients. Long-term follow-up shows good overall survival. The majority of all patients did not suffer from WCD shocks nor did receive ICD shocks after subsequent implantation. Patient selection regarding predictive conditions on long-term risk of ventricular tachyarrhythmias needs further risk stratification.
format Online
Article
Text
id pubmed-7141506
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71415062020-04-15 The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up Rosenkaimer, Stephanie L. El-Battrawy, Ibrahim Dreher, Tobias C. Gerhards, Stefan Röger, Susanne Kuschyk, Jürgen Borggrefe, Martin Akin, Ibrahim J Clin Med Article Background: The wearable cardioverter-defibrillator (WCD) is available for patients at high risk for sudden cardiac death (SCD) when immediate implantable cardioverter-defibrillator (ICD) implantation is not possible or indicated. Patient selection remains challenging especially in primary prevention. Long-term data on these patients is still lacking. Methods: 153 patients were included in this study. They were prescribed the WCD between April 2012 and March 2019 at the University Medical Center, Mannheim, Germany. The mean follow-up period was 36.2 ± 15.6 months. Outcome data, including all-cause mortality, were analyzed by disease etiology and ICD implantation following WCD use. Results: We analyzed 56 patients with ischemic cardiomyopathy, 70 patients with non-ischemic cardiomyopathy, 16 patients with prior need for ICD/CRT-D (device for cardiac resynchronization therapy with defibrillator) explanation, 8 patients with acute myocarditis and 3 patients with congenital diseases. 58% of the patients did not need ICD/CRT-D implantation after WCD use. 4% of all patients suffered from appropriate WCD shocks. 2 of these patients (33%) experienced appropriate ICD shocks after implantation due to ventricular tachyarrhythmias. Long-term follow-up shows a good overall survival. All-cause mortality was 10%. There was no significant difference between patients with or without subsequent ICD implantation (p = 0.48). Patients with ischemic cardiomyopathy numerically showed a higher long-term mortality than patients with non-ischemic cardiomyopathy (14% vs. 6%, p = 0.13) and received significantly more ICD shocks after implantation (10% of ischemic cardiomyopathy (ICM) patients versus 3% of non-ischemic cardiomyopathy (NICM) patients, p = 0.04). All patients with ventricular tachyarrhythmias during WCD use or after ICD implantation survived the follow-up period. Conclusion: Following WCD use, ICD implantation could be avoided in 58% of patients. Long-term follow-up shows good overall survival. The majority of all patients did not suffer from WCD shocks nor did receive ICD shocks after subsequent implantation. Patient selection regarding predictive conditions on long-term risk of ventricular tachyarrhythmias needs further risk stratification. MDPI 2020-03-24 /pmc/articles/PMC7141506/ /pubmed/32214048 http://dx.doi.org/10.3390/jcm9030893 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rosenkaimer, Stephanie L.
El-Battrawy, Ibrahim
Dreher, Tobias C.
Gerhards, Stefan
Röger, Susanne
Kuschyk, Jürgen
Borggrefe, Martin
Akin, Ibrahim
The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up
title The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up
title_full The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up
title_fullStr The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up
title_full_unstemmed The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up
title_short The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up
title_sort wearable cardioverter-defibrillator: experience in 153 patients and a long-term follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141506/
https://www.ncbi.nlm.nih.gov/pubmed/32214048
http://dx.doi.org/10.3390/jcm9030893
work_keys_str_mv AT rosenkaimerstephaniel thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT elbattrawyibrahim thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT drehertobiasc thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT gerhardsstefan thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT rogersusanne thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT kuschykjurgen thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT borggrefemartin thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT akinibrahim thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT rosenkaimerstephaniel wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT elbattrawyibrahim wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT drehertobiasc wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT gerhardsstefan wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT rogersusanne wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT kuschykjurgen wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT borggrefemartin wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup
AT akinibrahim wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup